ProShare Advisors
PDLI

ProShare Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

ProShare Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-32,038
Closed -$101K – 2121
2020
Q3 		$101K Sell
32,038
-2,034
-6% -$6.5K ﹤0.01% 1526
2020
Q2 		$99K Buy
34,072
+11,765
+53% +$37.2K ﹤0.01% 1568
2020
Q1 		$63K Sell
22,307
-17,658
-44% -$56.9K ﹤0.01% 1107
2019
Q4 		$130K Sell
39,965
-3,784
-9% -$11K ﹤0.01% 1663
2019
Q3 		$94K Sell
43,749
-6,294
-13% -$16.8K ﹤0.01% 1558
2019
Q2 		$157K Sell
50,043
-15,134
-23% -$49.1K ﹤0.01% 1484
2019
Q1 		$242K Buy
65,177
+597
+0.9% +$2.02K ﹤0.01% 1365
2018
Q4 		$187K Sell
64,580
-12,252
-16% -$33.7K ﹤0.01% 1388
2018
Q3 		$202K Sell
76,832
-6,037
-7% -$14.8K ﹤0.01% 1603
2018
Q2 		$194K Sell
82,869
-7,979
-9% -$22.3K ﹤0.01% 1622
2018
Q1 		$267K Sell
90,848
-15,931
-15% -$43.5K ﹤0.01% 1387
2017
Q4 		$293K Buy
106,779
+7,921
+8% +$24.3K ﹤0.01% 1402
2017
Q3 		$335K Buy
98,858
+950
+1% +$2.64K ﹤0.01% 1102
2017
Q2 		$242K Sell
97,908
-11,609
-11% -$26.7K ﹤0.01% 1267
2017
Q1 		$249K Sell
109,517
-27,793
-20% -$61.5K ﹤0.01% 1340
2016
Q4 		$291K Buy
137,310
+15,190
+12% +$42.4K ﹤0.01% 1385
2016
Q3 		$409K Sell
122,120
-22,506
-16% -$71.4K 0.01% 1028
2016
Q2 		$454K Buy
144,626
+1,965
+1% +$6.55K 0.01% 1016
2016
Q1 		$475K Sell
142,661
-12,771
-8% -$39.8K 0.01% 1021
2015
Q4 		$550K Buy
155,432
+14,558
+10% +$60.9K 0.01% 998
2015
Q3 		$709K Sell
140,874
-19,890
-12% -$114K 0.01% 797
2015
Q2 		$1.03M Sell
160,764
-9,841
-6% -$65.9K 0.01% 762
2015
Q1 		$1.2M Buy
170,605
+21,496
+14% +$156K 0.01% 762
2014
Q4 		$1.15M Sell
149,109
-2,581
-2% -$20.4K 0.01% 789
2014
Q3 		$1.13M Sell
151,690
-30,263
-17% -$281K 0.02% 1034
2014
Q2 		$1.76M Sell
181,953
-72,057
-28% -$642K 0.02% 840
2014
Q1 		$2.11M Buy
254,010
+177,669
+233% +$1.52M 0.03% 713
2013
Q4 		$644K Sell
76,341
-64,948
-46% -$547K 0.01% 1043
2013
Q3 		$1.13M Buy
141,289
+20,323
+17% +$163K 0.03% 786
2013
Q2 		$934K Buy
+120,966
New +$943K 0.02% 893

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

ProShare Advisors's PDLI Position: Q4 2020 in Review

ProShare Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 32,038 shares — an estimated $101K sold.

ProShare Advisors first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $2.11M in Q1 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • ProShare Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • ProShare Advisors sold 32,038 PDL BioPharma, Inc. shares in Q4 2020, an estimated $101K.
  • ProShare Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • ProShare Advisors's PDL BioPharma, Inc. position peaked at $2.11M in Q1 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on ProShare Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.